Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To Know

Articles From: Benzinga
Website: Benzinga


Benzinga Staff Writer

Krystal Biotech Inc KRYS has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB).

  • DEB is a genetic skin disorder affecting skin and nails that cause the skin to be very fragile and to blister easily. 
  • Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching.
  • Vyjuvek is a non-invasive, topical, and redosable gene therapy.
  • 67% of wounds treated with Vyjuvek achieved the primary endpoint of investigator-assessed complete wound healing at the six-month timepoints compared to 22% of wounds treated with placebo.
  • 71% of wounds treated with Vyjuvek achieved the secondary endpoint of complete wound healing at the three-month timepoints compared to 20% of wounds treated with placebo.
  • Vyjuvek was well tolerated. No drug-related serious adverse events or discontinuations due to treatment were reported. 
  • During the trial, one mild drug-related adverse event was reported.
  • Krystal plans to file an FDA marketing application in 1H of 2022 and a European application shortly after. 
  • Also See: Krystal Biotech’s KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin Condition.
  • Price Action: KRYS shares are up 114.30% at $85.31 during the premarket session on the last check Monday.

Originally Posted on November 29, 2021 – Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To Know

Disclosure: Benzinga

© 2022 Benzinga does not provide investment advice. All rights reserved.

Disclosure: Interactive Brokers

Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Benzinga and is being posted with its permission. The views expressed in this material are solely those of the author and/or Benzinga and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.